Bionano Genomics (BNGO) Enterprise Value (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Enterprise Value data on file, last reported at -$13.7 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 24.9% year-over-year to -$13.7 million; the trailing twelve-month figure through Mar 2026 stood at -$13.7 million (up 24.9% YoY), and the FY2025 full-year result was -$13.3 million, up 34.12% from the prior year.
• Enterprise Value fell to -$13.7 million in Q1 2026, from -$13.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$5.1 million in Q4 2022 to a low of -$216.5 million in Q1 2022.
• A 5-year average of -$62.2 million and a median of -$21.6 million in 2025 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value surged 97.97% in 2022 and plunged 1211.55% in 2023, its largest moves.
• Tracing BNGO's Enterprise Value over 5 years: stood at -$5.1 million in 2022, then sank by 1211.55% to -$66.8 million in 2023, then surged by 69.79% to -$20.2 million in 2024, then jumped by 34.12% to -$13.3 million in 2025, then declined by 3.02% to -$13.7 million in 2026.
• Business Quant data shows BNGO's Enterprise Value at -$13.7 million in Q1 2026, -$13.3 million in Q4 2025, and -$21.6 million in Q3 2025.